News & Events

HTG Announces Issuance of Two Method Patents Related to its Technology

TUCSON, Ariz., Sept. 20, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the United States Patent and Trademark Office has issued two U.S. Patents covering HTG’s technology and applications of its technology. 

The first patent, U.S. Patent 9,758,829 entitled Molecular Malignancy in Melanocytic Lesions, was issued to HTG and the John Wayne Cancer Institute, who co-invented the technology. It claims a method of treating an indeterminate or atypical nevi that involves measuring the nucleic acid expression of certain biomarkers, including MAGEA2, PRAME, PDIA4, NR4A1, PDLIM7, B4GALT1, SAT1, RUNX1, and SOCS3. The patent will expire in June 2033.

full press release

Posted on:

Return To List

Page last updated December 20, 2017